Physician profile
Louis C Johnson
NPI 1245225937
$8,749.18
in general payments reported to CMS, 2019-2025
34 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $758 · 2021: $897 · 2022: $1,441 · 2023: $1,408 · 2024: $1,838 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,391.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,656.96 | 2019-2025 | |
| Novo Nordisk INC | $1,592.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,141.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $601.87 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $467.42 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $399.47 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.82 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $305.04 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $264.58 | 2019-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $207.65 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.64 | 2019-2024 | Ofev, Jardiance |
| Abbott Laboratories | $189.53 | 2022-2025 | Freestyle Libre 3 |
| Allergan, INC. | $176.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $147.69 | 2019-2023 | Steglatro, Belsomra |
| Exact Sciences Corporation | $128.80 | 2023-2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $120.02 | 2024 | Korlym |
| Abbvie INC. | $117.85 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $85.44 | 2019-2022 | |
| Amarin Pharma, INC. | $79.60 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $70.77 | 2023-2024 | Rexulti |
| Inspire Medical Systems, INC. | $55.66 | 2024 | Inspire |
| Endogastric Solutions, INC | $54.72 | 2022 | |
| Sumitomo Pharma America, INC. | $49.58 | 2023-2025 | Gemtesa |
| Dynavax Technologies Corporation | $47.68 | 2023-2025 | Heplisav-B |
| Neuronetics, INC. | $45.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $45.12 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.36 | 2019-2022 | |
| Eisai INC. | $32.96 | 2021-2022 | |
| Daiichi Sankyo INC. | $21.97 | 2024 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $19.07 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.59 | 2023 | Unithroid |
| Ibsa Pharma INC. | $14.23 | 2025 | Licart, Flector, Tirosint |
| Senseonics, Incorporated | $12.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.